IMPORTANCE Evidence for the long-term efficacy and safety of anti-tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis is lacking.
T he management of skin sarcoidosis is still based on small trials and case series, mainly because therapeutic strategy depends on visceral prognosis. Limited skin lesions are generally treated with topical steroids, tetracycline antibiotics, or hydroxychloroquine, 1 despite a low level of evidence for efficacy. In case of failure or extensive and/or stigmatizing lesions, such as lupus pernio, systemic steroids (SS) and/or immunosuppressive agents (IS) have been shown to be useful. 2 Thalidomide is also considered in some patients, despite a negative trial and potential adverse effects. 3 High-quality trials demonstrating efficacy of anti-tumor necrosis factor α agents (anti-TNF) for the treatment of severe skin sarcoidosis are few. We investigated the efficacy and tolerance of anti-TNF in 46 patients.
Methods
STAT (Sarcoidosis Treated with Anti-TNF) is a French national voluntary retrospective and prospective database investigating the efficacy and safety of anti-TNF in sarcoidosis. Inclusion criteria in STAT were as follows: diagnosis of histologically proven sarcoidosis made in accordance with the guidelines of the World Association of Sarcoidosis and Other Granulomatous diseases, 4 age older than 18 years, and current or previous treatment with anti-TNF. The initiation of anti-TNF therapy in each participating center was decided by the referral physician, according to real-life standard practice. Patients provided written consent for inclusion, and physicians collected the following data: demographics, characteristics of the disease at baseline (ie, initiation of anti-TNF), previous treatments, concomitant SS or IS, and adverse events (AEs). The severity scoring for each organ (including skin) used the ePOST (extra-pulmonary Physician Organ Severity Tool) ranging from 0 (not affected) to 6 (very severe involvement).
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All patients with skin involvement at baseline were included in the present study. The primary end point was the overall cutaneous response rate (OCRR) to anti-TNF at 3, 6, and 12 months; complete response was defined as a cutaneous ePOST score 0 or 1 and partial response was defined as a decrease or 2 or more points from baseline. Secondary objectives included AEs, steroid sparing, and relapses.
Categorical variables were compared using the χ 2 test and continuous variables were compared using the Wilcoxon rank sum test. We first assessed efficacy and safety in the whole cohort and then compared patients with a skin-only indication for anti-TNF (Group 1) and patients treated for visceral involvement (Group 2). The response rates and infections, according to the duration of exposure, were described by Kaplan-Meier analysis. Univariate analyses of the predictor of response and infection were conducted using the log-rank test. All tests were 2-sided, and a P value less than .05 was considered significant. Analyses were performed using R statistical software, version 3.2.2 (R Foundation) for χ 2 analyses and Stata 14.0 (StataCorp LLC) for log-rank analyses. In France, observational studies that do not change routine patient management do not require ethics committee or institutional review board approval; all patients included in the STAT database provided informed consent.
Results
Forty-six patients of 140 included in the STAT database had skin lesions (Table) . A total of 66 individual courses of anti-TNF were administrated (14 patients received more than 1 course). Anti-TNF were administered with SS (mean dose of prednisone of 17.5 mg/d) in 28 cases (61%) and IS (methotrexate n = 26) in 32 cases (69.5%). Group 1 consisted of 21 patients; Group 2, 25 patients. The median (range) follow-up was 45 (3-109) months.
Overall cutaneous response rate is presented in Figure 1 , and Figure 2 shows an example of a complete cutaneous response. The mean dose of SS decreased from 17.5 mg/d at baseline to 8.4 mg/d at the last follow-up (P < .001).
In univariate analysis, OCRR was associated with nodules but not with other lesions (lupus pernio, plaques), age, sex, or duration of the disease.
Fourteen patients (30%) experienced 21 infectious AEs: urinary tract infections (n = 6), bronchopneumonitis (n = 7), sinusitis (n = 2), dental abscess, cellulitis, angiocholitis, herpes zoster, flu, and gastroenteritis (n = 1 for each). Seven patients (50%) were hospitalized for infection (grade 3/4): pneumonitis (n = 3), urinary tract infection, herpes zoster, facial cellulitis, and angiocholitis (n = 1 for each). Treatment was discontinued in 4 patients (3 for pneumonitis and 1 for facial cellulitis) and a patient in his 80s treated with concomitant prednisone of 40 mg/d and azathioprine died of pneumonitis. Thirteen of 14 patients who experienced infections were receiving SS and/or IS.
Sixteen patients with response stopped treatment (10 for AE; 6 for remission); 8 of these patients relapsed with a relapse rate of 20% at 1 year and 44% at 18 months. Treatment was resumed for 5 patients who had achieved previous remission with a response rate of 100%. Ten patients stopped first-line anti-TNF because of failure. Five patients received a second anti-TNF with efficacy in 3 cases.
Among 31 patients who responded to anti-TNF, 11 patients (35%) relapsed during treatment. Relapse occurred for 8 patients during dose spacing or reduction of anti-TNF (n = 3)
Key Points
Question What is the long-term efficacy and safety of anti-tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis?
Findings In this multicenter observational study of 46 patients with sarcoidosis and skin involvement who were treated with anti-TNF, the overall cutaneous response rate was 24% after 3 months, 46% after 6 months, and 79% after 12 months. Eleven (24%) patients stopped anti-TNF because of adverse events, and patients treated for visceral involvement had significantly more infections (48% vs 9.5%), and relapses occurred in half of the patients after discontinuation of anti-TNF.
Meaning Anti-TNF agents are effective against cutaneous sarcoidosis with a low infectious rate in patients treated for skin involvement.
or tapering of the concomitant SS (n = 3) or IS (n = 2). The outcome was favorable for 8 patients upon resumption of the prior treatment, shortening of the dosing interval, and/or increasing the dose of steroids. Anti-TNF was definitively discontinued in the other 3 patients.
By comparing groups, cutaneous ePOST scores at baseline were higher in Group 1 (5 vs 3; P < .001). 
Discussion
This large multicenter observational study showed that: (1) anti-TNF agents were effective in treating cutaneous sarcoidosis with an OCRR of 46% at 6 months and 79% at 12 months after the initiation of treatment; (2) anti-TNF had a significant steroid-sparing effect; (3) in total, 11 patients (24%), among whom one died, had to stop anti-TNF due to AEs (5 being infectious); (4) 14 of 46 patients (30%) experienced infections of varying severity, especially patients from Group 2 compared with Group 1 (n = 12 of 25 [48%] vs n = 2 of 21 [9.5%], respectively); (5) relapses occurred in almost half of the patients after discontinuation, but all patients in whom anti-TNF was discontinued because of remission achieved remission again upon resuming anti-TNF.
In our study, we showed similar OCRR as previous studies.
6-10 Response was rather slow. In the literature, infliximab and adalimumab are the most effective anti-TNF in sarcoidosis, but questions remain regarding dose and duration of therapy. In our series, anti-TNF had a suspensive effect. Expert consensus on the use of anti-TNF for the treatment of sarcoidosis has recommended gradually prolonging the interval between injections before discontinuing anti-TNF to limit the risk of relapses.
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We found more infections in patients of Group 2, who received more SS and IS. The overall cutaneous response rate was 24% (95% CI, 14%-40%) after 3 months, 46% (95% CI, 32%-62%) after 6 months, and 79% (95% CI, 64%-98%) after 12 months. Median ePOST severity score decreased from 5 at baseline to 3 at the last follow-up. Among a total of 31 responders, 13 achieved complete response and 18 achieved partial response as best response during follow-up.
Efficacy and Tolerance of Anti-TNF α Agents in Cutaneous Sarcoidosis
Brief There is little consensus in the literature on the increased risk of infection with anti-TNF treatment when used in combination with SS and/or IS vs monotherapy. Similar rates of infection were observed in the treatment of inflammatory bowel diseases in randomized clinical trials 12 and reports to the US Food and Drug Administration, 13 but a clear increased risk of infection with combination therapy has been described in observational studies.
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Limitations
Limitations were the volunteer inclusion in STAT, heterogeneous severity of cases, and unknown reproducibility of ePOST for skin lesions. However, the ePOST score was the simplest tool to evaluate severity and response i n a l l o r g a n s . A d v e r s e e f f e c t s c o u l d h a v e b e e n underreported.
Conclusions
Anti-TNF agents are effective in cutaneous sarcoidosis, but relapses are frequent after discontinuation. Clinicians must be aware of infections, especially if patients are being treated with concomitant SS or IS. Over time, as the heat sources causing EIA have evolved, so have the names by which it is commonly referred. One of the earliest documented descriptions was in 1842 during a medical school lecture on skin diseases when a condition referred to as "ephileis ignealis" (fiery freckle) was described as a mottled skin appearance on a woman's legs after exposure to a charcoal brazier. 1 Later in 1901, at the Dermatological Society of Great Britain and Ireland meeting, a similar case was described in a young woman who had the habit of sitting near an open fire for long periods of time. 2 In 1911, British dermatologist Horatio George Adamson, MD, described a case in a young man whose job as a cabinet-maker's assistant required that he stand in front of a fireplace for most of the day. Due to these associations with open fires, this eruption commonly became known as "fire stains." Around the same time, the German dermatologist, Abraham Buschke, MD, coined a new term, Hitze melanose (melanosis induced by heat), after observing many cases of reticulated discoloration caused by proximity to peat stoves. As central heating became more commonplace, the heat source associated with EIA transitioned from open fires to electric blankets. These blankets were frequently used in northern climates by elderly women for warmth during the winter. Based on the presentation on thighs and upper legs as well as the predominant demographic affected, EIA become fondly referred to as "Granny's tartan." Occupational-related causes of EIA also began to be recognized in bakers and chefs who would develop the rash on their face, palms, and arms leading to the name "toasted skin syndrome."
More recently, studies have emerged attributing EIA to the use of heat for relief of pain from chronic diseases such as pancreatitis and Crohn disease ("hot water bottle rash"). 3 With the advent of advanced technologies, EIA has also resurfaced in modern societies with culprits that include laptops (laptop thigh), car seat heaters, space heaters, and sauna belts. While the course of EIA is relatively benign, the presentation may be of special concern for both patients and unsuspecting physicians alike. Identification and removal of heat exposure with consideration of new modern sources is thus of utmost importance.
